Acalabrutinib: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Acalabrutinib, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
Item
Content
New predicted indications
None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug
4
Evidence level
Not applicable
Australia Market Status
Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items
1 (valid: 1)
Known uses recorded for this drug
Approved (supported by a licence or label)
Indication
Source
leukemia, lymphocytic, chronic, b-cell
licence in another country
Related to an approved indication (same disease category)
Indication
Approved category
none
none
Relations recorded in the knowledge graph (no approval found)
Indication
b-cell neoplasm
lymphosarcoma
mantle cell lymphoma
Australia Market Information
Licence
Product
Dosage form
Status
13318Y
CALQUENCE
Tablet 100 mg
Valid
Cytotoxicity
Item
Content
Cytotoxicity Classification
Targeted therapy (covalent BTK inhibitor)
Myelosuppression Risk
Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification
Please refer to the Product Information (PI) warnings and precautions
Monitoring Items
Please refer to the PI; typically includes full blood count and liver and renal function
Handling Protection
Please refer to the PI and local cytotoxic drug handling policies
Safety Considerations
No warnings or contraindications were available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
Drug Interactions: 100 interactions were identified, and the first 20 were reviewed. Major-level interactions include:
Aprepitant
Acetylsalicylic acid
Clarithromycin
Dexlansoprazole
Esomeprazole
Lansoprazole
Moderate-level interactions include antacids (aluminium hydroxide, calcium carbonate, magnesium salts, magaldrate), H2 blockers (cimetidine, famotidine), clotrimazole, dexamethasone, fenfluramine and dexfenfluramine, glycerol phenylbutyrate, and metreleptin. Acid-reducing agents and CYP3A modulators warrant particular attention when prescribing.
Disclaimer
This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.